Indaptus Therapeutics
INDP
47 hedge funds and large institutions have $49.4M invested in Indaptus Therapeutics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
31% more funds holding
Funds holding: 36 → 47 (+11)
39% less capital invested
Capital invested by funds: $80.9M → $49.4M (-$31.6M)
90% less call options, than puts
Call options by funds: $303K | Put options by funds: $3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.49M |
| 2 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$3.28M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$3.28M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$1.54M |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$845K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$9.46M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$1.66M |
| 3 |
6CM
683 Capital Management
New York
|
-$1.1M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$984K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$479K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
6CM
51
683 Capital Management
New York
| – | -$1.1M | -67 | Closed |
|
|
PC
52
PA Capital
Richmond,
Virginia
| – | -$225K | -14 | Closed |
|
|
MWNA
53
Marshall Wace North America
New York
| – | -$117K | -7 | Closed |
|
|
PWM
54
PRW Wealth Management
Quincy,
Massachusetts
| – | -$28K | -2 | Closed |
|
55
Citigroup
New York
| – | -$2K | – | – |
|
|
WCM
56
Whitener Capital Management
Rocky Mount,
North Carolina
| – | -$1K | – | – |
|
INDP Hedge Fund Activity: Q2 2019 in Review
47 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q2 2019, worth a combined $49.4M — down 39% from $80.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new INDP positions and 5 closed out — a net gain of 11 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $3.49M. The largest seller was Avoro Capital Advisors, cutting an estimated $9.46M.
- 47 institutional investors held Indaptus Therapeutics (INDP) as of Q2 2019, up from 36 in Q1 2019.
- Funds reported $49.4M of Indaptus Therapeutics stock for Q2 2019, down 39% quarter-over-quarter.
- 16 funds opened new Indaptus Therapeutics positions in Q2 2019 and 5 closed out, a net change of +11 holders.
- The largest Indaptus Therapeutics buyer in Q2 2019 was Sphera Funds Management, an estimated $3.49M added.
- The largest Indaptus Therapeutics seller in Q2 2019 was Avoro Capital Advisors, an estimated $9.46M sold.
Based on aggregated 13F filings for Q2 2019.